Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease.
The antioxidant N-acetylcysteine (NAC) or placebo was administered in a double-blind fashion to patients who met National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association criteria for probable AD. Testing for efficacy occurred after 3 and 6 months of treatment. Comparison of interval change favored NAC treatment on nearly every outcome measure, although significant differences were obtained only for a subset of cognitive tasks.
Adair
J C
JC
Neurology Service, Albuquerque Veterans Affairs Medical Center, New Mexico, USA.
Knoefel
J E
JE
Morgan
N
N
D000111:Acetylcysteine / Q000008:administration & dosage* / Q000009:adverse effects; D000544:Alzheimer Disease / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D016166:Free Radical Scavengers / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008297:Male; D016896:Treatment Outcome
D016166:Free Radical Scavengers; D000111:Acetylcysteine